It would be convenient to obtain a single blood sample for numerous blood te~ ting purposes from the patient using conventional syringe and/or vacutainer without specialized equipment of the type referred to above. Patent 3,999,538 and the apparatus described in my U.S. The measurement of whole blood rheocohesion is described in my earlier U.S. However, problems in obtaining a correct rheocohesion value include: improper venipuncture causing artifacts in the readings so obtained special equipment is needed to accurately measure the rate of flow of blood through a hypodermic needle inserted directly into the blood vessel of a patient under study while maintaining controlled conditions of standard pressure, temperature and time whole blood rheocohesion is an indirect measurement, and artifacts such as the hematocrit and total serum protein mus~ be considered. _ _ The measurement of the flow of blood through a device to measure blood viscosity, termed rheocohesion in the art, is a valuable diagnostic procedure.

G01N2333/745- Assays involving non-enzymic blood coagulation factors.

G01N2333/435- Assays involving biological materials from specific organisms or of a specific nature from animals from humans.

G01N2333/00- Assays involving biological materials from specific organisms or of a specific nature.

blood, urine Testing involving biospecific ligand binding methods Immunological testing involving blood coagulating time or factors, or their receptors

G01N33/86- Chemical analysis of biological material, e.g.

blood, urine Testing involving biospecific ligand binding methods Immunological testing

G01N33/50- Chemical analysis of biological material, e.g.

G01N33/00- Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00.

G01N- INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES.

Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Application filed by PHILPOT VAN BUREN filed Critical PHILPOT VAN BUREN Application granted granted Critical Publication of CA1218001A publication Critical patent/CA1218001A/en Status Expired legal-status Critical Current Links Original Assignee PHILPOT VAN BUREN Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Expired Application number CA000445500A Other languages French ( fr) Google Patents Serum fibrinogen viscosity in clinical medicine Google Patents CA1218001A - Serum fibrinogen viscosity in clinical medicine This correlation may be useful for anticipating the need for repeat plasmapheresis.CA1218001A - Serum fibrinogen viscosity in clinical medicine Serum viscosity and electrophoresis are recommended before and after plasmapheresis in order to correlate viscosity and M-spike with patient symptoms. Hyperviscosity syndrome can also occur in multiple myeloma patients.īecause the ability of a monoclonal protein to cause hyperviscosity is affected by its concentration, molecular weight, and aggregation, sera with concentrations of monoclonal IgM greater than 4 g/dL, IgA greater than 5 g/dL, or IgG greater than 6 g/dL should be tested for hyperviscosity. The most common cause of serum hyperviscosity is the presence of large concentrations of IgM monoclonal proteins, and Waldenstrom macroglobulinemia accounts for 80% to 90% of hyperviscosity cases. Funduscopic examination reveals dilation of retinal veins and flame shaped retinal hemorrhages. Hyperviscosity may be manifested by nasal bleeding, blurred vision, headaches, dizziness, nystagmus, deafness, diplopia, ataxia, paresthesias, or congestive heart failure. Viscosity is the property of fluids to resist flow.

Serum viscosity units